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cated fragment: Implication for PTH measurements in renal failure. of hypercalcemia not only is PTH suppressed, but the
J Clin Endocr Metab 84:4287–4290, 1999
parathyroid gland degrades a greater amount of biologi-3. Wang M, Hercz G, Sherrard D, et al: Relationship between intact
cally active PTH, forming fragments that are biologicallyPTH (1-84) parathyroid hormone and bone histomorphometry pa-
rameters in dialysis patients without aluminium toxicity. Am inactive [5, 6]. The serum calcium in our end-stage renal
J Kidney Dis 26:836–844, 1995 disease (ESRD) patients was 9.1 6 0.19 and in our trans-4. Cohen Solal M, Sebert J, Boudailliez B, et al: Comparison of
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mone for the diagnosis of bone disease in hemodialysed patients. PTH is only one of many factors involved in the patho-
J Clin Endocrinol Metab 73:516–524, 1991 genesis of ABD. Diabetes, hypercalcemia, interleukins,
cytokines, and the Rank-/Rankl system all have a role
in bone remodeling. Thus, the two situations (ESRD vs.Reply from the author
transplant) are not identical and the conclusions made
Fournier et al raise concerns regarding our paper [1] by Fournier et al do not apply to our paper.
and the work of Quarles et al [2] and Wang et al [3].
Although we agree with those investigators and believe Eduardo Slatopolsky for the authors
St. Louis, Missourithey are excellent publications, it is not our responsibility
to defend these papers. With regard to the criticisms of
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our paper, we and others [4] have collected sufficient partment of Medicine, Washington University School of Medicine, Box
8126, 660 S. Euclid, St. Louis, MO 63110, USA.information that emphasize that bone biopsy is the only
“gold standard” procedure that precisely defines changes
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